Collectively, although BCR-ABL can confer the autonomous growth capacity on LSCs, subsequent CML development and the responsiveness to drugs can be markedly modulated by signals provided by bone marrow microenvironments, particularly the hematopoietic niche. Here, ABL1 is linked to chronic myelogenous leukemia, BCR-ABL1 positive.